SEC Tracker
Get the app

Frazier Lifesciences Acquisition

Frazier Lifesciences Acquisition Q1 FY21: net income $2.8M

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Frazier Lifesciences Acquisition reported for Q1 FY21, the quarter ended Mar 31, 2021, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income$2.8MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Cash and cash equivalents$1.2MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  3. Cash from operations$202KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

View on EDGAR

Open in the app

Get an email when Frazier Lifesciences Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (6770) and public float not reported.

  1. AEI CapForce II Investment AEIB
  2. AIS Holdings Group AIDG
  3. Aimfinity Investment Corp. I AIMTF
  4. APx Acquisition Corp. I APXIF
  5. Aquaron Acquisition AQUC

Data on this page was fetched . The filing on SEC.gov is the record.